Organogenesis (ORGO) Competitors $6.22 +3.15 (+102.67%) Closing price 03:59 PM EasternExtended Trading$6.45 +0.23 (+3.66%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ORGO vs. WVE, EVO, SDGR, AMPH, APGE, IMCR, ARQT, KNSA, DYN, and SNDXShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Wave Life Sciences (WVE), Evotec (EVO), Schrödinger (SDGR), Amphastar Pharmaceuticals (AMPH), Apogee Therapeutics (APGE), Immunocore (IMCR), Arcutis Biotherapeutics (ARQT), Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Wave Life Sciences Evotec Schrödinger Amphastar Pharmaceuticals Apogee Therapeutics Immunocore Arcutis Biotherapeutics Kiniksa Pharmaceuticals Dyne Therapeutics Syndax Pharmaceuticals Organogenesis (NASDAQ:ORGO) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings. Do institutionals and insiders believe in ORGO or WVE? 49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are owned by institutional investors. 36.9% of Organogenesis shares are owned by insiders. Comparatively, 29.1% of Wave Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor ORGO or WVE? Wave Life Sciences received 267 more outperform votes than Organogenesis when rated by MarketBeat users. Likewise, 67.78% of users gave Wave Life Sciences an outperform vote while only 66.44% of users gave Organogenesis an outperform vote. CompanyUnderperformOutperformOrganogenesisOutperform Votes9766.44% Underperform Votes4933.56% Wave Life SciencesOutperform Votes36467.78% Underperform Votes17332.22% Which has stronger earnings & valuation, ORGO or WVE? Organogenesis has higher revenue and earnings than Wave Life Sciences. Organogenesis is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$455.04M1.72$4.95M-$0.02-311.10Wave Life Sciences$53.61M30.07-$57.51M-$1.11-9.52 Is ORGO or WVE more profitable? Organogenesis has a net margin of -1.62% compared to Wave Life Sciences' net margin of -66.50%. Organogenesis' return on equity of -2.69% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-1.62% -2.69% -1.63% Wave Life Sciences -66.50%-280.57%-52.90% Does the media prefer ORGO or WVE? In the previous week, Organogenesis had 3 more articles in the media than Wave Life Sciences. MarketBeat recorded 13 mentions for Organogenesis and 10 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 0.74 beat Organogenesis' score of 0.37 indicating that Wave Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Wave Life Sciences 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ORGO or WVE? Organogenesis presently has a consensus price target of $5.00, suggesting a potential downside of 19.64%. Wave Life Sciences has a consensus price target of $22.60, suggesting a potential upside of 113.81%. Given Wave Life Sciences' higher possible upside, analysts clearly believe Wave Life Sciences is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility and risk, ORGO or WVE? Organogenesis has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.09, suggesting that its stock price is 209% less volatile than the S&P 500. SummaryOrganogenesis and Wave Life Sciences tied by winning 9 of the 18 factors compared between the two stocks. Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$782.27M$7.21B$5.83B$8.60BDividend YieldN/A2.79%4.74%3.95%P/E Ratio-103.706.3025.4619.20Price / Sales1.72190.64391.10111.70Price / Cash15.7265.6738.0634.58Price / Book2.956.607.544.42Net Income$4.95M$139.69M$3.19B$247.08M7 Day Performance93.83%-3.43%-3.06%-3.27%1 Month Performance74.78%-5.44%-3.69%-4.89%1 Year Performance78.28%-11.42%12.66%7.34% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis2.8867 of 5 stars$6.22+102.7%$5.00-19.6%-14.2%$782.27M$455.04M-103.70950News CoverageGap UpHigh Trading VolumeWVEWave Life Sciences4.0849 of 5 stars$10.48-5.8%$22.22+112.0%+107.1%$1.60B$53.61M-9.44240Analyst ForecastGap DownEVOEvotec1.8175 of 5 stars$4.46+0.5%$5.93+33.0%-42.6%$1.58B$845.74M0.005,061SDGRSchrödinger1.8315 of 5 stars$21.69-4.2%$32.11+48.0%-32.8%$1.58B$216.67M-9.27790Earnings ReportAnalyst ForecastNews CoverageAMPHAmphastar Pharmaceuticals4.3922 of 5 stars$32.29+3.2%$50.33+55.9%-43.2%$1.55B$723.55M10.761,761News CoverageGap DownAPGEApogee Therapeutics3.0546 of 5 stars$33.37-3.4%$89.71+168.8%-12.3%$1.50BN/A-13.7991IMCRImmunocore1.2573 of 5 stars$29.99+0.2%$65.64+118.9%-58.0%$1.50B$249.43M-31.57320Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeARQTArcutis Biotherapeutics3.4888 of 5 stars$12.39-4.8%$16.60+34.0%+20.4%$1.45B$59.61M-6.92150Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageKNSAKiniksa Pharmaceuticals2.3951 of 5 stars$19.63-1.9%$36.60+86.4%-6.0%$1.42B$270.26M-140.20220Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionDYNDyne Therapeutics3.2208 of 5 stars$13.59-3.0%$49.91+267.2%-46.5%$1.38BN/A-3.82100Earnings ReportAnalyst ForecastNews CoverageSNDXSyndax Pharmaceuticals3.7617 of 5 stars$15.67-4.3%$36.20+131.0%-37.4%$1.34B$16M-4.32110 Related Companies and Tools Related Companies Wave Life Sciences Alternatives Evotec Alternatives Schrödinger Alternatives Amphastar Pharmaceuticals Alternatives Apogee Therapeutics Alternatives Immunocore Alternatives Arcutis Biotherapeutics Alternatives Kiniksa Pharmaceuticals Alternatives Dyne Therapeutics Alternatives Syndax Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORGO) was last updated on 2/28/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
